---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039769"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:06:36.936502+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics Q2 net loss $15.6M; cash $116.2M after $46.7M placement

## Summary
- Cash and investments $116.2M at June 30, 2023, up from $82.7M at March 31, 2023.
- Net loss $15.6M for Q2 2023 vs $14.4M in Q2 2022; R&D expense flat at $10.8M.
- ENLIGHTEN I Phase 3 enrollment completion expected in weeks; data 1H 2024.
- BEACON Phase 2 topline results for LYR-220 now expected September 2023.
- Private placement closed May 31, 2023 yielded net proceeds of $46.7M.

## SEC filing metadata
- accession: 0000950170-23-039769
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000095017023039769/0000950170-23-039769-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000095017023039769/lyra-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039769
- JSON: https://secwatch.observer/filing/0000950170-23-039769.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039769.txt

## Key facts
- Earnings Releases
  Lyra Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $15.6 million.
  - Period: the second quarter ended June 30, 2023
  - Net income: $15.6 million
  - Result: reported results
  source text: Net loss for the quarter ended June 30, 2023 was $15.6 million compared to $14.4 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1327273/000095017023039769/0000950170-23-039769-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.